23rd BioAsia 2026

In his valedictory address, D. Sridhar Babu emphasized the forward-looking Life Sciences Policy 2026–2030, noting that it will continue to evolve alongside industry needs. He highlighted increased strategic budget allocation from the Government of Telangana to strengthen quality infrastructure, the development of 10 new industrial parks between ORR and the Regional Ring Road to accelerate sector growth, and stronger talent-building initiatives through advanced life sciences education, while also applauding the innovation and impact demonstrated by this year’s startup award winners. #BioAsia #TechBioUnleashed #LifeSciencesSummit #GlobalHealthcare #lifesciences #BioAsia2026 #aihealthcareindia #InnovationInTechBio #futureofhealthcare

Global collaboration and future-focused healthcare innovation took centre stage at BioAsia 2026, where Barnabe Delarze from Swissnex spoke about the vast potential of India as a rapidly expanding life sciences market. He underlined the opportunity to address metabolic diseases through digital innovation, highlighting alternate, behaviour-driven approaches that target disease at its root, pointing toward a future where technology-enabled preventive healthcare can work alongside or reduce reliance on traditional drug-based treatments. #BioAsia #TechBioUnleashed #LifeSciencesSummit #GlobalHealthcare #lifesciences #BioAsia2026 #aihealthcareindia #InnovationInTechBio #futureofhealthcare

At BioAsia 2026, industry voices like Shylender Bijapur and Patrick Morsch reflected on the growing global confidence in India as an emerging pharmaceutical and life sciences powerhouse. Their perspective reinforces how the country’s deep talent pool, expanding research ecosystem, and accelerating innovation momentum are positioning it as a key destination shaping the future of global healthcare and pharmaceutical advancement. #BioAsia #TechBioUnleashed #LifeSciencesSummit #GlobalHealthcare #lifesciences #BioAsia2026 #aihealthcareindia #InnovationInTechBio #futureofhealthcare

Powering the future of breakthrough science and manufacturing, BioAsia 2026 featured Financing TechBio & DeepTech Manufacturing, bringing together leading investor perspectives on scaling high-impact innovation. The session included insights from Mr. Ajay Mahipal, Mr. Karthik Narayanaswamy, Mr. Sunil Thakur, and Dr. Ramesh Byrappaneni, and was moderated by Mr. Atin Tomar. Discussions highlighted how investors evaluate risk in deep tech and advanced biotech, strategies to de-risk innovation, and the growing opportunity to scale breakthrough technologies from India to the global stage. #BioAsia #TechBioUnleashed #LifeSciencesSummit #GlobalHealthcare #lifesciences #BioAsia2026 #aihealthcareindia #InnovationInTechBio #futureofhealthcare

At BioAsia 2026, India’s Innovation Moment: Scaling the Next Phase of Global Impact brought together leading voices across research, industry, and global business to examine India’s fast-evolving innovation landscape. The session featured insights from Dr. Jitendra Kumar, Dr. Murali Ramachandra, Mr. Sridhar Gopal, Mr. Nataraj Kalyanaraman, Mr. Sanjeev Sachdeva, Mr. Raja Jammalamadaka, and Mr. Greg Killian, and was moderated by Mr. Vikas Dandekar. Discussions highlighted India’s rapid innovation growth, while addressing critical challenges across funding, talent, and commercialization needed to accelerate global impact at scale. #BioAsia #TechBioUnleashed #LifeSciencesSummit #GlobalHealthcare #lifesciences #BioAsia2026 #aihealthcareindia #InnovationInTechBio #futureofhealthcare

From policy to research, from innovation to real-world healthcare impact, our esteemed dignitaries share powerful perspectives at BioAsia 2026, reflecting a shared commitment to advancing global health through collaboration and science-led progress. #BioAsia #TechBioUnleashed #LifeSciencesSummit #GlobalHealthcare #lifesciences #BioAsia2026 #aihealthcareindia #InnovationInTechBio #futureofhealthcare

Marking a significant moment for the life sciences ecosystem, Sri D. Sridhar Babu, Hon’ble Minister for Industries and Commerce, Government of Telangana, attended the inauguration of BioAsia 2026. During his address, he reaffirmed Hyderabad’s global leadership in vaccine manufacturing, highlighting its recognition as the Vaccine Capital of the World and its growing role in shaping the future of global healthcare and life sciences innovation. #BioAsia #TechBioUnleashed #LifeSciencesSummit #GlobalHealthcare #lifesciences #BioAsia2026 #aihealthcareindia #InnovationInTechBio #futureofhealthcare

Shaping healthcare outcomes where it matters most, Making It Matter: How GCCs Transform Capability into End-Patient Impact brought together global perspectives at Bio Asia 2026 under the moderation of Ms. Shalini Pillay. Panelists Mr. Siva Kumar Padmanabhan, Ms. Esha Juneja, Dr. Anand Jain, Mr. Manish Arora, Mr. Mahesh Natarajan and Mr. Srinivas Peddi discussed ageing demographics, critical patient pricing, cross-border complexities, and embedding AI at the core of GCC transformation. The session, led in collaboration with KPMG, also marked the release of a whitepaper capturing real-world patient impact stories from healthcare GCCs. #BioAsia #TechBioUnleashed #LifeSciencesSummit #GlobalHealthcare #lifesciences #BioAsia2026 #aihealthcareindia #InnovationInTechBio #futureofhealthcare

At BioAsia 2026, Swathi Rathor from Sai Life Sciences reflected the strength of the BioAsia platform in bringing together global pharma, biotech, and life sciences stakeholders. BioAsia continues to serve as a key hub for industry engagement, collaboration, and ecosystem growth, reinforcing its role in advancing innovation, partnerships, and the future of healthcare and life sciences. #BioAsia #TechBioUnleashed #LifeSciencesSummit #GlobalHealthcare #lifesciences #BioAsia2026 #aihealthcareindia #InnovationInTechBio #futureofhealthcare

At BioAsia 2026, the panel discussion on Building Innovation-First GCCs: AI, R&D & Digital Transformation set the tone for how global capability centers are evolving into innovation powerhouses. The session opened with a keynote by Mr. Anton Groom, followed by a dynamic discussion moderated by Dr. Purav Gandhi, featuring insights from Mr. Badhri Srinivasan, Mr. Syed Naveed, Mr. Sanjay Patel, Mr. Som Chattopadhyay, and Ms. Gail Horwood. The conversation focused on how AI-led transformation, integrated R&D strategies, and digital-first operating models are enabling GCCs to move beyond support functions to become drivers of enterprise-wide innovation and long-term value creation. #BioAsia #TechBioUnleashed #LifeSciencesSummit #GlobalHealthcare #lifesciences #BioAsia2026 #aihealthcareindia #InnovationInTechBio #futureofhealthcare

At BioAsia 2026, Ms. Madeline Roach (EVP, Head of Business Operations, Sanofi, France) spotlighted the real impact of AI in healthcare, from strengthening governance frameworks and improving accountability for outcomes, to enabling smarter resource allocation and reducing program delivery costs. Reinforcing a future-ready mindset, she shared a powerful perspective: AI will not replace humans, but humans with AI will replace humans without AI #BioAsia #TechBioUnleashed #LifeSciencesSummit #GlobalHealthcare #lifesciences #BioAsia2026 #aihealthcareindia #InnovationInTechBio #futureofhealthcare

At BioAsia 2026, Dr. Stefan Miltenyi delivered a keynote on Cell and Gene Therapies: From Scientific Breakthroughs to Scalable Global Impact. He noted that the CGT market is projected to reach 100 billion dollars, highlighting that while CGT is revolutionary, it is highly complex and requires integrated ecosystems. He also emphasised that India is well positioned to serve as a gateway for advancing CGT over the next decade. #BioAsia #TechBioUnleashed #LifeSciencesSummit #GlobalHealthcare #lifesciences #BioAsia2026 #aihealthcareindia #InnovationInTechBio #futureofhealthcare

At BioAsia 2026, the Genome Valley Excellence Award was presented to Prof. Bruce L. Levine by the Hon’ble Chief Minister Revanth Reddy, recognising his pioneering contributions to cancer therapy innovation. In his keynote, he spoke about advancements enhancing CAR T Cell Therapy and highlighted the future potential of in vivo CAR T cell generation using lipid nanoparticle technology to transform cancer treatment outcomes and expand access to next-generation therapies globally. #BioAsia #TechBioUnleashed #LifeSciencesSummit #GlobalHealthcare #lifesciences #BioAsia2026 #aihealthcareindia #InnovationInTechBio #futureofhealthcare

At BioAsia 2026, Dr. Pushmeet Kohli shared insights on the transformative impact of AlphaFold on biological research, highlighting the importance of solving root node problems in science. The session explored coding and non-coding mutations and their role in disease understanding, along with the emerging potential of Alpha Genome in advancing large-scale genomic interpretation and accelerating next-generation discovery in life sciences. #BioAsia #TechBioUnleashed #LifeSciencesSummit #GlobalHealthcare #lifesciences #BioAsia2026 #aihealthcareindia #InnovationInTechBio #futureofhealthcare

Bringing global expertise onto one platform with a shared focus on solving complex healthcare challenges through innovation, research, and strategic collaboration. The continued convergence of ideas and perspectives reflects a unified global effort to drive next-generation life sciences growth and real-world healthcare transformation. This is what BioAsia 2026 is all about, creating a global platform where science, partnership, and purpose come together to shape the future of healthcare. #BioAsia #TechBioUnleashed #LifeSciencesSummit #GlobalHealthcare #lifesciences #BioAsia2026 #aihealthcareindia #InnovationInTechBio #futureofhealthcare

At BioAsia 2026, every interaction contributes to a larger vision of transforming healthcare through science, technology, and collaboration. As delegates and industry leaders engage across sessions, exhibitions, and networking spaces, the focus remains on accelerating innovation and building solutions that address global healthcare needs. If you have not registered yet, secure your spot and be part of the conversations shaping the future of healthcare: bioasia.in/2026/registrat… For detailed agenda, please visit: bioasia.in/2026/agenda.php #BioAsia #TechBioUnleashed #LifeSciencesSummit #GlobalHealthcare #lifesciences #BioAsia2026 #aihealthcareindia #InnovationInTechBio #futureofhealthcare

At BioAsia 2026, Chetan Mallik from Novartis reflected the strong community spirit that defines the BioAsia platform. The event continues to bring together global industry leaders, partners, and ecosystem stakeholders, reinforcing BioAsia’s role as a key meeting ground for collaboration, relationship-building, and advancing the life sciences industry through shared vision and long-term partnerships. If you have not registered yet, secure your spot and be part of the conversations shaping the future of healthcare: bioasia.in/2026/registrat… For detailed agenda, please visit: bioasia.in/2026/agenda.php #BioAsia #TechBioUnleashed #LifeSciencesSummit #GlobalHealthcare #lifesciences #BioAsia2026 #aihealthcareindia #InnovationInTechBio #futureofhealthcare

At BioAsia 2026, the panel discussion on Next-Gen Biologics & Advanced Modalities: From Discovery to Clinical Proof & CMC at Scale, moderated by Mr. Gil Bashe, featured Dr. Raches Ella, Dr. Darrin Morrissey, Dr. Sangita Reddy, Mr. V. Simpson Emmanuel, Dr. José Castillo, Dr. Madhuri Vusirikala, and Dr. Stefan Miltenyi. The discussion highlighted next-generation biologics, cell and gene therapies, mRNA and radiopharmaceuticals, with generative AI and advanced computational tools supporting decisions across design, development, analytics and manufacturing readiness. If you have not registered yet, secure your spot and be part of the conversations shaping the future of healthcare: bioasia.in/2026/registrat… For detailed agenda, please visit: bioasia.in/2026/agenda.php #BioAsia #TechBioUnleashed #LifeSciencesSummit #GlobalHealthcare #lifesciences #BioAsia2026 #aihealthcareindia #InnovationInTechBio #futureofhealthcare

At BioAsia 2026, Dr. Stefan Miltenyi delivered a keynote on Cell and Gene Therapies: From Scientific Breakthroughs to Scalable Global Impact. He noted that the CGT market is projected to reach 100 billion dollars, highlighting that while CGT is revolutionary, it is highly complex and requires integrated ecosystems. He also emphasised that India is well positioned to serve as a gateway for advancing CGT over the next decade. #BioAsia #TechBioUnleashed #LifeSciencesSummit #GlobalHealthcare #lifesciences #BioAsia2026 #aihealthcareindia #InnovationInTechBio #futureofhealthcare